Talk:Corynanthe johimbe

Internal copy/paste

Some content from Yohimbine was copied here today. Jytdog (talk) 23:34, 4 May 2015 (UTC)

images

i looked in the commons, .gov sites, internet achive, and google images for free images but didn't find any. Jytdog (talk) 00:54, 5 May 2015 (UTC)

Random editor please help

I don't really know how to edit the article properly so hopefully someone else can move this over. The statement "By itself, yohimbe bark is on the FDA list of banned substances" is simply not true; and it isn't really supported by its webMD source. Yohimbine is a prescription medication in the US, UK<4>, and AUS<3>. The yohimbe bark and yohimbe bark extract are sold in many dietary supplements in the US, some of which are standardized to a given concentration amount of yohimbine. Yohimbine is not on the WADA<2>, NSF<2>, or NFL<2> banned substance list for athletes. Some countries including United Kingdom, Ireland, Netherlands, Belgium, Denmark, Czeck Rupublic, Canada, Australia, and New Zealand have banned yohimbe bark and/or it's extract from being sold as a food and/or dietary supplement <1, plus consistent with other sources>

Sources: <1> EFSA Journal 2013;11(7):3302 <2> Verified from respective lists, I don't have the web-addresses off-hand <3> The yohimbine article correctly links to the AUS S4 status. <4> I verified this somewhere in the UK regulations...

If someone fixes this; thanks! — Preceding unsigned comment added by 208.87.237.201 (talk) 01:31, 15 December 2015 (UTC)

I read the source material, copyedited and changed the WebMD reference (to NIH MedlinePlus) cautioning about lack of scientific definition and concern for safety. From review of several source materials, my conclusion is that this is an unsafe extract and should be avoided for human consumption. --Zefr (talk) 03:39, 15 December 2015 (UTC)

I had made this original note in the talk and have read the sourced materials. I made some changes to the updates made by Zefr to improve the neutrality and clarify between the bark/extract and between use as a drug or dietary supplement. I do not take and do not recommend taking yohimbe bark or yohimbine. Anadverb (talk) 05:20, 15 December 2015 (UTC)anadverb

Available as prescription drug was removed as unsourced by Zefr. Since it is used as a veterinary drug and it is banned as a supplement it seems important to mention that it is a prescription in countries that the supplement is banned in; not mentioning this gives the impression that there is stronger regulatory control against this substance than there actually is. The EFSA makes it clear that there have been multiple pharacutical trials; but in fairness to Zefr it does not explicitly say whether or not any of these were available and/or are still approved. They are, which I verified with multiple sources but I don't know what qualifies as "sourcable". Drugs.com has a list of prescription drugs of yohimbine. I independently verified that some of these drugs really do exist and are active b/c I don't know if drugs.com is reliable (Some of them may also be no longer available btw, but I did find at least two that appeared to be actively available and I did not check all 13). I also independently verified from UK banned substances and AUS banned substances that yohimbine is legal by prescription only (hence banned in dietary supplements). So, what am I supposed to source? I also have no idea how to add sources, the other information was all supported by sources that others had already identified on this page. — Preceding unsigned comment added by Anadverb (talk • contribs) 16:11, 15 December 2015 (UTC)

"Prescription" implies rigorous regulatory review and approval following substantial scientific documentation, such as provided by the US FDA or Australia's Therapeutic Goods Administration, among other national regulatory agencies. The science and safety of yohimbine are so thin that I feel confident it has not been approved as a prescription drug anywhere. But I'm open to your research which needs to supply a WP:SECONDARY source meeting WP:MEDRS if it identifies a clinical condition specifically where yohimbine intervenes against a disease. --Zefr (talk) 16:24, 15 December 2015 (UTC)

Merge Proposal

I think that Burantashi should be merged with this article. A couple journal articles such as this one [1]https://www.researchgate.net/publication/339004535_SUB-ACUTE_HEPATOTOXICITY_OF_PAUSINYSTALIA_YOHIMBE_BARK_EXTRACT_BURANTASHI_IN_MALE_ALBINO_RATS_RATTUS_NOVERGICUS are worded in a way that make me think Burantashi is a brand or local name of powdered yohimbe. Lalaithan (talk) 09:04, 4 December 2022 (UTC)

I agree. If you search 'Burantashi' on Google Scholar you find a handful of papers, of variable quality, but what they do tell us is that 'burantashi' is a local name for a powder or extract of P. yohimbe bark, or in common parlance, yohimbe. There is no suggestion that Burantashi is anything different from yohimbe, and the article Burantashi does not claim or show otherwise. Therefore, there is no justification for having a separate article; it seems to be a clear case of content-forking by writing on the same topic under a different name. It should be merged.

That said, I do not agree that all the information in the Burantashi article should be automatically transferred across to the Corynanthe johimbe article. The normal rules should apply i.e. is it notable and is it adequately sourced. Now, the Burantashi article largely consists of a summary of a single paper (Ajayi et al, 2002), but this should not have been included in the first place. It nowhere mentions Burantashi. "The aim of the present study was to investigate the biochemical and physiological mechanisms underlying the penile relaxant effect of yohimbine, using rabbit and human isolated preparations of erectile tissue" (p.296). It is therefore yet another research paper on yohimbe. As to that, it is only a primary source, not evaluated in the secondary literature, as such not acceptable as per WP:PRIMARY. Ttocserp 11:24, 4 December 2022 (UTC)

Merged. Ttocserp 11:36, 12 December 2022 (UTC)